Antipsychotics: To combine or not to combine?

Psychiatria Danubina

Volumn 25, Issue 3, 2013, Pages 306-310

  Šagud, Marina ^a   Vuksan Čusa, Bjanka ^b   Živković, Maja ^c   Vlatković, Suzana ^d   Kramarić, Milivoj ^b   Bradaš, Zoran ^b   Mihaljević Peleš, Alma ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b KBC Zagreb   (Croatia)

^c Referentni centar za Alzheimerovu bolest i psihijatriju sta rijeivo t ne dobi   (Croatia)

^d Neuropsychiatric Hospital Ivan Barbot   (Croatia)

Author keywords

Antipsychotic polypharmacy (APP); Treatment of schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; ILOPERIDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; ZIPRASIDONE; ZOTEPINE;

AGE DISTRIBUTION; BIOGEOGRAPHIC REGION; CLINICAL PRACTICE; COGNITIVE DEFECT; CONFERENCE PAPER; CONSTIPATION; DISEASE DURATION; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG COST; DRUG MONITORING; DRUG POTENTIATION; EXTRAPYRAMIDAL SYMPTOM; HOSPITALIZATION; HUMAN; HYPERPROLACTINEMIA; MAXIMUM TOLERATED DOSE; METABOLIC SYNDROME X; MONOTHERAPY; ORTHOSTATIC HYPOTENSION; PARKINSONISM; POLYPHARMACY; REFRACTORY PERIOD; RISK ASSESSMENT; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; TACHYCARDIA; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; POLYPHARMACY; SCHIZOPHRENIA;

EID: 84885228987     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Aggarwal NK, Sernyak MJ, Rosenheck RA: Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications. J Clin Psychopharmacol 2012; 32:323-8.
2. Baandrup L, Sørensen J, Lublin H, Nordentoft M, Glenthoj B: Association of antipsychotic polypharmacy with health service cost: a register-based cost analysis. Eur J Health Econ 2012; 13:355-63.
3. Bernardo M, Coma A, Ibáñez C, Zara C, Bari JM, Serrano-Blanco A: Antipsychotic polypharmacy in a regional health service: a population-based study.BMC Psychiatry 2012; 15:12-42.
4. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14:87-96.
5. Chetty M, d'Esposito F, Zhang WV, Glen J, Dore G, Stankovic Z, Edwards RJ, Ramzan I, Murray M: In vitro and in vivo evaluation of the inhibition potential of risperidone toward clozapine biotransformation. Br J Clin Pharmacol 2009; 68:574-9.
6. Correll CU, Gallego JA: Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a longstanding clinical practice. Psychiatr Clin North Am 2012; 35:661-81.
7. Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, Covell NH: SchizophreniaTrials Network. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 2011; 168:702-8.
8. Fan X, Borba CP, Copeland P, Hayden D, Freudenreich O, Goff DC, Henderson DC: Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand 2013; 127:217-26.
9. Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU: Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 2012a; 138:18-28.
10. Gallego JA, Nielsen J, De Hert M, Kane JM, Correll CU: Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf 2012b; 11:527-42.
11. Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, Falkai P, Kapur S, Leucht S, Licht R, Naber D, O'Keane V, Papakostas G, Vieta E, Zohar J: Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol 2009; 19:520-32.
12. Hashimoto Y, Uno J, Miwa T, Kurihara M, Tanifuji H, Tensho M: Effects of antipsychotic polypharmacy on sideeffects and concurrent use of medications in schizophrenic outpatients. Psychiatry Clin Neurosci 2012; 66:405-10.
13. He M, Deng C, Huang XF: The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain. CNS Drugs 2013; 27:423-34.
14. Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC: Aripiprazole added to overweight and obese olanzapine- Treated schizophrenia patients. J Clin Psychopharmacol 2009a; 29:165.
15. Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Forstbauer SI, Miley K, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC: Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia. Hum Psychopharmacol 2009b; 24:225-32.
16. Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Carson WH, Pikalov A, Assunção-Talbott S: A multicenter, randomized, doubleblind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry 2009; 70:1348-57.
17. Kristensen D, Hageman I, Bauer J, J?rgensen MB, Correll CU: Antipsychotic Polypharmacy in a Treatment-Refractory Schizophrenia Population Receiving Adjunctive Treatment With Electroconvulsive Therapy. J ECT 2013 [Epub ahead of print]
18. Minzenberg MJ, Yoon JH. An index of relative central ?- adrenergic receptor antagonism by antipsychotic medications. Exp Clin Psychopharmacol 2011; 19:31-9.
19. Molina JD, Toledo-Romero F, López-Rodríguez E, Amorin-Díaz M, Lerma-Carrillo I, López-Muñoz F: Augmentation treatment with amisulpride in schizophrenic patients partially responsive toolanzapine. Pharmacopsychiatry 2011; 44:142-7.
20. Nielsen RE, Levander S, Thode D, Nielsen J: Effects of sertindole on cognition in clozapine-treated schizophrenia patients. ActaPsychiatr Scand 2012; 126:31-9.
21. Novick D, Ascher-Svanum H, Brugnoli R, Bertsch J, Hong J, Haro JM: Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophreniain the European Schizophrenia Outpatient Health Outcomes Study. J Nerv Ment Dis 2012; 200:637-43.
22. Potkin SG, Thyrum PT, Alva G, Bera R, Yeh C, Arvanitis LA: The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol 2002; 22:121-30.
23. Procyshyn RM, Honer WG, Wu TK, Ko RW, McIsaac SA, Young AH, Johnson JL, Barr AM: Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry 2010; 71:566-73.
24. Šagud M, Mihaljević-Peleš A, Begić D, Vuksan-Čusa B, Kramarić M, Živković M, Jakovljević M: Antipsychotics as antidepressants: what is the mechanism? Psychiatr Danub 2011; 23:302-7.
25. Sheppard C, Beyel V, Fracchia J, Merlis S: Polypharmacy in psychiatry: a multi-state comparison of psychotropic drug combinations. Dis Nerv Syst 1974; 35:183-9.
26. Stahl SM: Nuevasguíaspara el uso de la polifarmaciaantipsicótica. Rev Psiquiatr Salud Ment (Barc) 2013; 6:97-100.
27. Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, Miller AL, Rosenheck RA, Hsiao JK: CATIE Investigators. Schizophr Res 2009; 107:1-12.
28. Suokas JT, Suvisaari JM, Haukka J, Korhonen P, Tiihonen J: Description of long-term polypharmacy among schizophrenia outpatients. Soc Psychiatry Psychiatr Epidemiol 2013; 48:631-8.
29. Tada M, Shirakawa K, Matsuoka N, Mutoh S: Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. Psychopharmacology (Berl) 2004; 176:94-100.
30. Taylor DM, Smith L, Gee SH, Nielsen J: Augmentation of clozapine with a second antipsychotica meta-analysis. Acta Psychiatr Scand 2012; 125:15-24.
31. Teo C, Borlido C, Kennedy JL, De Luca V: The role of ethnicity in treatment refractory schizophrenia. Compr Psychiatry 2013; 54:167-72.
32. Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P: Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality inschizophrenia. Arch Gen Psychiatry 2012; 69:476-83.
33. Torre DL, Falorni A: Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag 2007; 3:929-51.
34. Xiang YT, Dickerson F, Kreyenbuhl J, Ungvari GS, Wang CY, Si TM, Lee EH, He YL, Chiu HF, Yang SY, Chong MY, Tan CH, Kua EH, Fujii S, Sim K, Yong MK, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Shinfuku N: Common use of antipsychotic polypharmacy in older Asian patients with schizophrenia (2001-2009). J Clin Psychopharmacol 2012; 32:809-13.
35. Ye W, Ascher-Svanum H, Tanji Y, Flynn JA, Takahashi M, Conley RR: Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis. Neuropsychiatr Dis Treat 2012; 8:259-66.
36. Živković M, Mihaljević-Peleš A, Božina N, Šagud M, Nikolac-Perković M, Vuksan-Čusa B, Muck-Šeler D: The Association Study of Polymorphisms in DAT, DRD2, and COMT Genes and Acute Extrapyramidal Adverse Effects in Male Schizophrenic Patients Treated With Haloperidol. J Clin Psychopharmacol 2013 [Epub ahead of print].